- Home
- RVYL vs MBIO Comparison
RVYL vs MBIO Comparison
Compare RVYL & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVYL
- MBIO
- Stock Information
- Founded
- RVYL 2007
- MBIO 2015
- Country
- RVYL United States
- MBIO United States
- Employees
- RVYL N/A
- MBIO N/A
- Industry
- RVYL Professional Services
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- RVYL Consumer Discretionary
- MBIO Health Care
- Exchange
- RVYL Nasdaq
- MBIO Nasdaq
- Market Cap
- RVYL 5.4M
- MBIO 4.7M
- IPO Year
- RVYL N/A
- MBIO N/A
- Fundamental
- Price
- RVYL $0.85
- MBIO $1.02
- Analyst Decision
- RVYL Hold
- MBIO
- Analyst Count
- RVYL 1
- MBIO 0
- Target Price
- RVYL N/A
- MBIO N/A
- AVG Volume (30 Days)
- RVYL 34.6M
- MBIO 87.6K
- Earning Date
- RVYL 08-12-2025
- MBIO 08-12-2025
- Dividend Yield
- RVYL N/A
- MBIO N/A
- EPS Growth
- RVYL N/A
- MBIO N/A
- EPS
- RVYL N/A
- MBIO N/A
- Revenue
- RVYL $54,357,000.00
- MBIO N/A
- Revenue This Year
- RVYL $27.50
- MBIO N/A
- Revenue Next Year
- RVYL $35.71
- MBIO N/A
- P/E Ratio
- RVYL N/A
- MBIO N/A
- Revenue Growth
- RVYL N/A
- MBIO N/A
- 52 Week Low
- RVYL $0.36
- MBIO $1.01
- 52 Week High
- RVYL $2.40
- MBIO $31.00
- Technical
- Relative Strength Index (RSI)
- RVYL 52.78
- MBIO 35.22
- Support Level
- RVYL $0.60
- MBIO $1.01
- Resistance Level
- RVYL $0.91
- MBIO $1.10
- Average True Range (ATR)
- RVYL 0.10
- MBIO 0.07
- MACD
- RVYL 0.02
- MBIO -0.02
- Stochastic Oscillator
- RVYL 57.41
- MBIO 3.45
About RVYL Ryvyl Inc.
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.